ARMATA PHARMACEUT.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudo… Read more
ARMATA PHARMACEUT. (TG1N) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ARMATA PHARMACEUT. (TG1N) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ARMATA PHARMACEUT. - Net Assets Trend (None–None)
This chart illustrates how ARMATA PHARMACEUT.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ARMATA PHARMACEUT. (None–None)
The table below shows the annual net assets of ARMATA PHARMACEUT. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ARMATA PHARMACEUT.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ARMATA PHARMACEUT. Competitors by Market Cap
The table below lists competitors of ARMATA PHARMACEUT. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nishoku Technology Inc
TW:3679
|
$112.09 Million |
|
M.C.S. Steel Public Company Limited
BK:MCS
|
$112.11 Million |
|
Kaltura Inc
NASDAQ:KLTR
|
$112.17 Million |
|
Tah Hsin Industrial Corp
TW:1315
|
$112.20 Million |
|
HeidelbergCement India Limited
NSE:HEIDELBERG
|
$112.07 Million |
|
Greenfire Resources Ltd.
NYSE:GFR
|
$112.05 Million |
|
Kongsberg Automotive ASA
PINK:KGAUF
|
$112.04 Million |
|
Agenus Inc
NASDAQ:AGEN
|
$112.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ARMATA PHARMACEUT.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ARMATA PHARMACEUT.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ARMATA PHARMACEUT. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ARMATA PHARMACEUT.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ARMATA PHARMACEUT. (TG1N) | €- | N/A | N/A | $112.09 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |